A Food Effect and QTc Study of Perifosine in Patients With Advanced Malignancies
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01224730|
Recruitment Status : Completed
First Posted : October 20, 2010
Last Update Posted : March 14, 2018
This is a Phase I study which will analyze any food-drug effects as well as QTc effects of perifosine. Safety and efficacy will also be evaluated.
Patients who complete the first 24 days on single agent perifosine may have the opportunity to 1) continue on single agent perifosine; 2) switch to the combination of capecitabine + perifosine; or 3) switch to the combination of sorafenib + perifosine.
|Condition or disease||Intervention/treatment||Phase|
|Cancer||Drug: perifosine||Phase 1|
- Patients with prior exposure to perifosine.
- Patients receiving any other chemotherapy, targeted agents, investigational agents or devices within four weeks (28 days) or 5 half‐lives of the agent(s), whichever is longer, prior to Day1 of study treatment.
- Patients must have finished radiotherapy 28 days prior to start of treatment. Radiotherapy is not permitted in the Treatment Phase. Palliative radiotherapy to single sites for symptom control is allowed only during the Continuation Phase. The clinical coordinator should be contacted prior to initiating radiotherapy in this setting.
- Patients who have had a major surgical procedure, open biopsy, or significant traumatic injury ≤4 weeks prior to Day 1 of study treatment.
- Patients with a serious non‐healing wound, active ulcer, or untreated bone fracture.
- Patients with known central nervous system (CNS) metastases. Patients with CNS metastases that have been treated and are stable and who do not require corticosteroid treatment for the metastases (off steroids > 4 weeks) will be allowed.
- Serious active infection requiring parenteral antibiotics or antifungal therapy.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to perifosine (miltefosine or edelfosine).
- Patients with known dipyrimidine dehydrogenase (DPD) deficiency or prior severe reaction to 5‐FU (for patients electing to receive capecitabine therapy in the Continuation Phase).
- Patients with known HIV or acute or chronic active Hepatitis B or Hepatitis C.
- Uncontrolled inter‐current illness including, but not limited to, ongoing or active infection and psychiatric illness/social situations that would Limit compliance with study requirements.
- Patients with a history of unstable or newly diagnosed angina pectoris, recent myocardial infarction (within 6 months of enrollment), or New York Heart Association class II‐IV congestive heart failure (Appendix B).
- Female patients who are pregnant or lactating. All females of childbearing potential must have a negative serum pregnancy test within 72 hours of treatment. Women of childbearing potential and men with partners of child‐bearing potential, must agree to employ adequate contraception to prevent pregnancy while on therapy and for 4 weeks after the completion of treatment (see Appendix C).
- A history of additional risk factors for Torsades de Pointes (e.g. familial long QT syndrome, hypokalemia, heart failure (Appendix B), left ventricular hypertrophy, slow heart rate (<45 bpm)).
- Required use of concomitant medications known to prolong the QT/QTc interval
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||24 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Food Effect and QTc Study of Perifosine in Patients With Advanced Malignancies|
|Actual Study Start Date :||January 24, 2012|
|Actual Primary Completion Date :||November 4, 2013|
|Actual Study Completion Date :||November 4, 2013|
Experimental: Perifosine 100 mg
Perifosine 100 mg orally daily under Fed and Fasted conditions
100 mg daily
- To evaluate the effects of food on the PK profile and bioavailability of perifosine, and to evaluate the effects of perifosine treatment on ECG parameters [ Time Frame: 24 days ]
- To assess the Pharmacokinetic profile of perifosine when given to patients under fed and fasted conditions
- To evaluate changes in other ECG parameters associated with perifosine treatment (ventricular rate, PR interval, QRS interval, QT interval)
- To evaluate the safety and efficacy of perifosine when given to patients with advanced malignancies [ Time Frame: Up to 6 months ]
- To evaluate the safety profile (adverse events) and efficacy (response rate, and time to progression) of all study patients treated with perifosine.
- After Day 24, to evaluate the safety profile (adverse events) and efficacy (response rate and time to progression) of all study patients who remain on single agent perifosine, switch to the combination of capecitabine + perifosine or switch to the combination of sorafenib + perifosine.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01224730
|United States, Texas|
|Dallas, Texas, United States, 75230|
|Houston, Texas, United States, 77030|
|Study Director:||Ed Cullen, PhD||Keryx / AOI Pharmaceuticals, Inc.|